STOCK TITAN

[144] Adaptive Biotechnologies Corp SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Adaptive Biotechnologies insider sale reported: Chad M. Robins reported multiple sales of Common Stock under Rule 144, with transactions dated between 01/05/2026 and 03/03/2026. The reported lots include individual sales such as 41,666 shares, 99,225 shares, 116,334 shares, and others, each with an accompanying cash amount in USD. The filings list broker details and aggregate per‑lot proceeds; timing and direction are sales as reported.

Positive

  • None.

Negative

  • None.

Insights

Multiple Rule 144 sales by CEO reported across January–March 2026.

The filings list repeated dispositions of Common Stock by Chad M. Robins, showing individual trade sizes such as 41,666, 99,225, and 116,334 shares with per‑lot proceeds in USD.

These are compliance‑style disclosures under resale rules; cash‑flow recipients and broader ownership impact require referenced holdings or subsequent filings to assess materiality.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Adaptive Biotechnologies

NASDAQ:ADPT

ADPT Rankings

ADPT Latest News

ADPT Latest SEC Filings

ADPT Stock Data

2.45B
150.48M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SEATTLE